Entero Healthcare Solutions LimitedENTEROCorporate

Pharmacy Retail Latest results: Jun 2026 14 quarters of data

₹1,585.00

MCap ₹6,898 Cr · P/E 300.4

Entero Healthcare Solutions Limited — Stock analysis & AI research Entero Healthcare Solutions Limited — Seasonality — best & worst months Entero Healthcare Solutions Limited — Technical indicators & charts Entero Healthcare Solutions Limited — Technical setup — score, trend, support & resistance Entero Healthcare Solutions Limited — Live exchange announcements

📋 High Sales Growth Stocks 📋 High Profit Growth Stocks 📋 Stocks With Strong Quarterly Results 📈 SuperTrend Bearish Signal

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹83 Cr

Sales · Jun 2026

+4.9% YoY

₹-10 Cr

Operating Profit · Jun 2026

+29.3% YoY

-11.6%

OPM % · Jun 2026

+32.9% YoY

₹3 Cr

Net Profit · Jun 2026

-50.3% YoY

₹0.79

EPS · Jun 2026

-50.6% YoY

📝 Entero Healthcare Solutions Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Entero Healthcare Solutions Limited reported revenue of ₹83 crore for the quarter ended June 2026 (Q1 FY27), up 4.9% from ₹79 crore in the same quarter last year, and up 5.4% sequentially over the March 2026 quarter.

Net profit fell 50.3% year-on-year to ₹3 crore, from ₹7 crore. Earnings per share (EPS) came in at ₹0.79.

Operating profit stood at ₹-10 crore — an operating margin (OPM) of -11.6%, compared with -17.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Entero Healthcare Solutions Limited posted revenue of ₹348 crore, a decline of 48.5% over FY25, with a net profit of ₹26 crore (up 119.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹352 crore with a net profit of ₹23 crore.

Valuation snapshot

At the current price of ₹1,585.00, ENTERO has a market capitalisation of ₹6,898 crore and a trailing P/E of about 300.4.

Within the Pharmacy Retail industry, it is the 2nd-largest of the 2 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 52.40%, foreign institutional investors (FIIs) 4.37%, domestic institutional investors (DIIs) 15.48%, public shareholders 27.75% of Entero Healthcare Solutions Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹6,898 Cr

Current Price ?

₹1,585.0

P/E ?

300.43above ind

Industry P/E ?

43.60

P/B ?

4.10

P/S ?

19.59

P/FCF ?

-91.98

Enterprise Value ?

₹7,031 Cr

EV/EBITDA ?

-118.84

PEG ?

4.69

Earnings Yield ?

-1.0%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹352 Cr

OPM ?

-16.8%

Profit after tax (TTM) ?

₹23 Cr

EPS (TTM) ?

₹5.28

ROCE ?

2.0%

ROE ?

1.4%

ROA ?

1.1%

Growth

Sales — latest qtr ?

₹83 Cr

PAT — latest qtr ?

₹3 Cr

YoY qtr sales growth ?

4.9%

YoY qtr profit growth ?

-50.3%

Sales growth (3y) ?

25%

Sales growth (5y) ?

27%

Profit growth (3y) ?

64%

Profit growth (5y) ?

30%

Financial Health

Debt ?

₹133 Cr

Debt to Equity ?

0.08

Interest Coverage ?

-15.0

Current Ratio ?

N/A

Ownership

Promoter holding ?

52.40%

Change in promoter holding ?

-0.02%

Pledged percentage ?

N/A

Market

Return 3 months ?

35.0%

Return 6 months ?

24.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	50	61	74	77	107	122	113	369	72	79	83	107	79	83	+4.9%	+5.4%
Operating Profit	-7	-8	-9	-8	-9	-2	-6	4	-12	-14	-13	-14	-23	-10	+29.3%	+57.9%
Other Income	14	15	17	16	42	32	29	10	26	26	24	23	40	23	-12.0%	-42.1%
Interest	3	5	7	5	6	0	0	5	0	1	1	1	3	6	+866.7%	+91.4%
Depreciation	3	2	2	2	2	2	2	4	2	3	3	3	3	3	+10.1%	+3.6%
Profit Before Tax	1	0	-2	1	26	28	20	5	-36	9	8	1	12	5	-49.7%	-61.6%
Net Profit	1	2	-2	1	37	21	15	4	-28	7	6	1	13	3	-50.3%	-73.4%
EPS	1.56	5.74	-1.33	0.27	10.19	4.80	3.52	0.84	-6.39	1.60	1.31	0.18	3.08	0.79	-50.6%	-74.4%
OPM %	-14.0%	-13.1%	-12.2%	-11.1%	-8.6%	-1.5%	-5.4%	1.0%	-16.5%	-17.3%	-15.1%	-13.0%	-29.1%	-11.6%	+32.9%	+60.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹677 Cr	₹348 Cr	₹352 Cr	-48.5%
Operating Profit	₹-16 Cr	₹-63 Cr	₹-59 Cr	-288.7%
OPM %	-2.40%	-18.14%	-16.80%	-655.8%
NPM %	1.78%	7.60%	6.52%	+327.0%
Other Income	₹97 Cr	₹114 Cr	₹111 Cr	+17.0%
Depreciation	₹10 Cr	₹12 Cr	₹12 Cr	+19.3%
Interest	₹7 Cr	₹5 Cr	₹10 Cr	-23.9%
EBIT	₹-26 Cr	₹-75 Cr	₹-71 Cr	-186.1%
PBT	₹17 Cr	₹30 Cr	₹26 Cr	+73.7%
Tax	₹5 Cr	₹5 Cr	₹4 Cr	-11.6%
Net Profit	₹12 Cr	₹26 Cr	₹23 Cr	+119.5%
EPS	₹2.77	₹6.17	₹5.36	+122.7%
Material Cost	₹640 Cr	₹229 Cr	₹189 Cr	-64.3%
Employee Cost	₹45 Cr	₹43 Cr	₹42 Cr	-2.8%
Extraordinary Items	₹47 Cr	₹4 Cr	₹4 Cr	-90.4%

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	4	43	44	44	+0.0%
Reserves	-84	1,583	1,607	1,640	+2.1%
Borrowings	775	18	14	133	+850.0%
Other Liabilities	68	125	139	342	+146.0%
Total Liabilities	764	1,769	1,804	2,158	+19.6%
Fixed Assets	41	34	28	50	+78.6%
CWIP	0	0	0	0	—
Investments	41	41	277	825	+197.8%
Other Assets	682	1,694	1,498	1,283	-14.4%
Total Assets	764	1,769	1,804	2,158	+19.6%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-57	-76	-109	-60	+45.0%
Cash from Investing Activity	-58	-763	208	-122	-158.7%
Cash from Financing Activity	91	926	-41	98	+339.0%
Net Cash Flow	-24	87	58	-84	-244.8%
Free Cash Flow	-57	-77	-111	-75	+32.4%
CFO/OP	124%	214%	305%	89%	-70.8%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	153	130	89	108	+21.3%
Inventory Days	68	65	110	85	-22.7%
Days Payable	132	88	87	87	+0.0%
Cash Conversion Cycle	89	107	112	107	-4.5%
Working Capital Days	947	850	432	366	-15.3%
ROCE %	-0%	4%	5%	2%	-60.0%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	52.42%	52.42%	52.42%	52.42%	52.40%	-0.0%
FIIs	17.21%	14.68%	5.14%	4.03%	4.37%	+8.4%
DIIs	10.19%	9.64%	16.42%	16.62%	15.48%	-6.9%
Public	20.19%	23.26%	26.03%	26.94%	27.75%	+3.0%
No. of Shareholders	33,338	36,334	40,333	39,084	39,709	+1.6%

⚖️ Peer comparison

Industry: Pharmacy Retail · 2 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	MEDPLUS Medplus Health	₹660.00	7,926	36.0	6,892	220	8.8%	3.2%	12.3%	46.5%	23.4%	25.5%
2	ENTERO Entero Healthcare	₹1,731.80	7,537	58.8	7,128	168	4.4%	2.4%	29.4%	36.3%	38.2%	72.2%

❓ Frequently asked questions

What was Entero Healthcare Solutions Limited's revenue in Q1 FY27?

What was Entero Healthcare Solutions Limited's net profit in Q1 FY27?